Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Chimagen Biosciences Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. The busiest examiner, CUNNINGCHEN, KATHLEEN MARY, is responsible for 1 pending office action.
The distribution of 2 pending office actions across 2 distinct examiners means that each examiner is handling 1 action. The presence of 2 distinct art units indicates that the company's biotechnological research is being examined in different specialized groups. This requires a prosecution strategy that can adapt to two different sets of art unit guidelines and examination styles.
With 1 pending action for the busiest examiner, the portfolio's activity is balanced between the 2 distinct examiners. This lack of concentration under a single examiner means the company must navigate two different sets of feedback. The involvement of 2 distinct art units further suggests that the applications cover different technical aspects of the biotechnology or pharmaceutical fields.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556665 | HETERODIMERIC ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556665 | HETERODIMERIC ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 15733195 | COVALENT MULTI-SPECIFIC ANTIBODIES | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556665 | HETERODIMERIC ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112 | Non-Final OA | — | Pending | Oct 21, 2023 |
| 15733195 | COVALENT MULTI-SPECIFIC ANTIBODIES | DEBERRY, REGINA M | 1647 | §103DP | Non-Final OA | — | Pending | Jun 08, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial